Matthew Barker, MD
Urogynecology and Reconstructive Pelvic Surgery · Sioux Falls, SDNPI 1588629570
Payments from drug & device makers
Across 566 payments — averaging $263.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$65K
- Astellas Pharma US Inc$55K
- Boston Scientific$15K
- Medtronic$6K
- Coloplast$2K
- AbbVie$1K
- plus $5K from 20 others
Across 1 payment — averaging $787.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$788
What the payments were for
- Consulting fees$69,33547%
- Speaking & faculty fees$44,85330%
- Travel & lodging$18,18412%
- Food & beverage$15,86811%
- Education$6440%
- Gifts$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 181 | $64,985 |
| Astellas Pharma US Inc | 117 | $54,603 |
| Boston Scientific | 32 | $15,105 |
| Medtronic(2 entities) | 93 | $6,104 |
| Coloplast | 36 | $1,560 |
| AbbVie(2 entities) | 39 | $1,490 |
| Provepharm Inc. | 2 | $1,380 |
| Caldera Medical, Inc | 13 | $1,119 |
| Applied Medical Resources Corporation | 3 | $1,042 |
| Carbon Medical Technologies, Inc. | 1 | $300 |
| 180 Medical, Inc. | 8 | $265 |
| AMAG Pharmaceuticals, Inc. | 5 | $185 |
| Sumitomo Pharma America, Inc. | 9 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $135 |
| Monaghan Medical Corporation | 1 | $71 |
| Laborie Medical Technologies Corp. | 2 | $59 |
| Northgate Technologies, Inc. | 1 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $50 |
| Ardelyx, Inc. | 3 | $48 |
| Rochester Medical Corporation | 2 | $38 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $33 |
| Urovant Sciences Inc | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| BD | 1 | $24 |
| Pfizer | 1 | $17 |
| Convatec Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$64,148
- Veozah$39,916
- MYRBETRIQ$7,998
- GENERAL - THERAPIES$7,511
- Bulkamid$6,878
- INTERSTIM$3,866
- Axonics r-SNM System$3,501
- BLUDIGO$1,380
- GelPOINT V-Path$992
- BOTOX$963
- Desara$852
- ALTIS$646
- InjecSure$300
- INTELLIS ADAPTIVESTIM$212
- UPSYLON$132
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 280 | $148,628 |
| MyrbetriqMirabegron | 191 | $102,227 |
| LinzessLinaclotide | 49 | $36,581 |
| PremarinEstrogens, Conjugated | 33 | $14,144 |
| Estradiol | 90 | $7,487 |
| Fosfomycin Tromethamine | 36 | $3,842 |
| Clobetasol Propionate | 74 | $2,065 |
| Methenamine Hippurate | 32 | $1,395 |
| Trospium Chloride | 32 | $1,141 |
| Cephalexin | 202 | $599 |
| Cefdinir | 30 | $338 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $188 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $157 | $148,628280 claims |
| Astellas Pharma US IncMyrbetriq | $54,603 | $102,227191 claims |
| AbbVieLinzess | $1,490 | $36,58149 claims |
| PfizerPremarin | $17 | $14,14433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in South Dakotaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Sioux Falls
- Kevin BensonSioux Falls$1.5M
- Michael FiegenSioux Falls$132
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.